Articles tagged with Prostate Cancer
A randomized clinical trial found that high-dose radiation therapy can generate an immune system response similar to vaccination, sparking a systemic immune reaction against cancer. Patients treated with stereotactic ablative radiotherapy lived significantly longer without disease progression.
Researchers have discovered that certain molecules in semen, known as miRNAs, may serve as non-invasive biomarkers for prostate cancer. The study found that these molecules can provide reliable information to help diagnose and predict the progression of the disease.
A national register study from Lund University found that fathers who underwent assisted reproduction, such as IVF and ICSI, had a 30-60% higher risk of developing prostate cancer compared to those who conceived naturally. The study also showed that men treated for infertility had a higher risk of prostate cancer at a young age.
Men who became fathers through assisted reproduction techniques have a higher risk of prostate cancer and early onset prostate cancer compared to those who conceived naturally. Early screening and long-term monitoring are advised for these men.
Researchers from the University of Bath screened over 20,000 molecules to find compounds that inhibit α-methylacyl-CoA racemase (AMACR) protein, increasing its levels in prostate cancer cells. This approach identified novel small-molecule inhibitors with potential therapeutic applications.
Researchers at George Washington University found a potential therapeutic target for prostate cancers with PTEN mutation by identifying the connection between PTEN and ARID4B genes. Suppressing ARID4B expression in cancer cells with PTEN mutation significantly inhibits cell growth and increases cell death.
Scientists at University of Bath have developed a new family of drugs that inhibit the AMACR protein, increasing effectiveness by 20-fold. The research provides promising avenues for treating prostate and other cancers.
A study found that men with the BRCA2 gene fault are almost twice as likely to be diagnosed with prostate cancer and develop more serious tumours. Regular PSA testing could help detect these cancers earlier.
The team aims to understand how genetics contributes to driving aggressive pathology in prostate cancer by combining pathology, computational modeling, and genomics. They plan to identify therapeutic options by testing combinations of genes in mouse models of the disease.
Researchers created a biosensor for detecting prostate cancer recurrence with high sensitivity and low cost. The device, like a home pregnancy test, provides immediate results and can help improve patient outcomes.
A new blood test detects early cancer cells in the bloodstream, predicting aggressive prostate cancer with high accuracy. Combining this test with the current PSA test reduces unnecessary biopsies and overtreatment of benign conditions.
A new study found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men. Regular mushroom intake was associated with an 8-17% lower risk of prostate cancer.
A large cohort study found that obesity is consistently associated with a greater burden of symptoms and experiences of distress among patients with breast or prostate cancer. Among patients with colon cancer, significant symptoms and distress were observed regardless of weight, suggesting alternative factors at play.
A new dual imaging approach combines transrectal ultrasound (TRUS) and photoacoustic imaging to detect anatomical features and molecular information of the prostate. This technology has shown promise in detecting prostate cancers with high accuracy, including distinguishing malignant regions in patients with advanced disease.
Researchers tested AuroLase Therapy, a treatment using gold-silica nanoshells, in 16 men with low- to intermediate-grade prostate cancer. The treatment was successful in 87.5 percent of lesions treated at one year of follow-up, preserving quality of life.
A cancer therapy invented at Rice University has shown promising results in clinical trials, destroying tumors without debilitating side effects. Thirteen of the first 15 prostate cancer patients treated with AuroLase Therapy showed no detectable signs of cancer a year after treatment.
Researchers from Bern, Switzerland have been awarded major grants by the US Department of Defense to study new treatments for prostate cancer and develop methods to preserve severed limbs. The projects aim to identify factors driving metastasis and improve survival rates in prostate cancer patients.
A large population-based study found that novel oral androgen signaling inhibitor therapies increase the risk of death in patients with pre-existing cardiovascular conditions. Patients with three or more heart conditions experienced a 50% increase in mortality, while enzalutamide was associated with lower hospitalization rates.
A study found that chaperone protein Hsp70 inhibits toxic protein aggregates in the androgen receptor, which causes Kennedy's disease and prostate cancer. Hsp70 may be useful as a therapeutic target to treat these conditions.
As people age, the prostate grows, leading to an increased risk for prostate cancer and benign prostatic hyperplasia. A new UCLA study found that older mice have more luminal progenitor cells, which can generate new prostate tissue, helping explain why the prostate tends to grow with age.
The study found that adjuvant radiotherapy improved disease-free period for patients with locally advanced prostate cancer, with 82% of patients in the treatment group remaining disease-free. However, the treatment did not significantly impact survival rates.
Researchers at UVA have identified Hullk, a non-coding RNA that regulates biological processes in cells. The discovery offers potential for targeting and stopping prostate cancer progression with fewer side effects.
Scientists at MD Anderson Cancer Center found that PRC1 regulates metastasis by suppressing the immune system, leading to tumor blood vessel growth. A novel PRC1 inhibitor showed efficacy as a single treatment and cooperated with immunotherapy to suppress metastasis.
A Penn study of over 150,000 men with prostate cancer found that hormone therapy increased the likelihood of developing Alzheimer's disease or dementia. The treatment was associated with a 14% increased risk of Alzheimer's and a 20% increased risk of dementia compared to patients who did not receive hormone therapy.
A study of 154,089 older men diagnosed with prostate cancer found that androgen deprivation therapy increased the likelihood of being diagnosed with Alzheimer disease or dementia. The therapy was associated with a higher risk over an average follow-up period of eight years.
Researchers identify DNA-PK as a master regulator of gene networks promoting aggressive prostate cancer behaviors. A clinical trial combining standard-of-care with a first-in-man DNA-PK inhibitor shows promising early results.
A new biomarker in urine helps detect aggressive prostate cancer, improving detection accuracy and reducing unnecessary treatments. The noninvasive test was found to accurately identify high-risk individuals and achieved similar accuracy as invasive tissue-based tests.
A new study from the University of Pennsylvania finds that proton therapy can be as effective and safe as traditional treatments when administered in higher doses over a shorter period. The research, which included 184 men with non-metastatic prostate cancer, showed low rates of serious gastrointestinal and urologic issues.
The study identified three ways in which the FOXA1 gene mutates to trigger prostate cancer: FAST, FURIOUS, and LOUD. Class 1 mutations cause rapid DNA traversal, class 2 mutations prevent normal FOXA1 from binding, and class 3 mutations create duplications of oncogenes. These alterations have different clinical implications for patients.
A novel combination therapy using two targeted treatments has shown to maximize efficacy while reducing side effects in men with progressive prostate cancer. The study found that nearly 70 percent of patients saw a more than 50 percent reduction in PSA levels after the treatment.
Researchers developed a urine test called 'PUR' that can diagnose aggressive prostate cancer and predict treatment needs up to five years earlier than standard methods. The test identified men who are up to eight times less likely to require treatment within five years of diagnosis.
Research shows that adding an interim scan during therapy can help guide patient treatment, predicting survival and tumor response. Interim scans using PSMA PET imaging have shown significant predictive value for overall survival in patients undergoing 177Lu-PSMA radioligand therapy.
A study by Mount Sinai researchers found that World Trade Center responders with prostate cancer exhibited chronic inflammation in their prostates, which may have contributed to their cancer. The researchers suggest that this link could lead to the development of anti-inflammatory therapies for similar cases.
Inflammatory and immune-regulatory mechanisms were altered in animal models and prostate cancer tumor samples of WTC responders. These findings suggest that exposure to World Trade Center dust may contribute to chronic inflammation, which can drive prostate cancer progression.
A new study by University of Surrey researchers found that community pharmacy interventions significantly improved physical activity levels and reduced weight, BMI, and cholesterol in men with prostate cancer. These lifestyle changes also led to increased grip strength and better overall fitness.
A new study found that the protein CCN3 is a key factor promoting prostate cancer invasion of bone and predicting poor outcomes. High CCN3 expression correlated with shortened overall survival and bone metastases, while low-expression groups had better survival rates.
Researchers at UCLA Health Sciences have developed a more effective method for detecting prostate cancer by combining biopsy strategies. The new approach, which includes MRI-guided biopsy, increased the rate of cancer detection to up to 33% compared to traditional methods.
A prospective study found that higher levels of abdominal and thigh fat are associated with an increased risk of aggressive prostate cancer. Men with a lower BMI showed a stronger association between visceral fat and advanced prostate cancer. Lifestyle interventions, such as diet and exercise, may also reduce the risk of prostate cancer.
A study found that only 15% of men in North Carolina with low or intermediate-risk prostate cancer who chose active surveillance followed recommended monitoring guidelines. This suggests that patients may not be adhering to the guidelines, which include regular PSA tests and biopsies. The study's authors call for further research into ...
Researchers at Duke University Medical Center discovered how prostate cancer cells develop to mimic bone-forming cells, enabling proliferation in the bone microenvironment. This understanding could lead to more effective use of radium-233 and development of new therapies to treat or prevent prostate cancer spread to bone.
A new study found that black men with low-risk prostate cancer are 16% less likely to adopt active surveillance than non-black men, despite similar rates of overall active surveillance. The disparity is attributed to socioeconomic and insurance barriers that deter black patients from accessing follow-up care.
A new device forces cells through tiny channels, detecting blebbing in cancer cells to identify metastatic prostate cancer. Highly metastatic cells exhibit more blebbing than normal or less-metastatic cells.
Researchers at Boston University School of Medicine have discovered that inhibiting the BRD4 protein can consistently regulate prostate cancer cell migration and invasion. The study provides promising insights into preventing the spread of castration-resistant prostate cancer (CRPC), a highly aggressive form of the disease.
Researchers have identified a promising therapeutic target for metastatic prostate cancer by inhibiting the PHLPP2 protein, which stabilizes the oncogenic protein MYC. This finding has implications for treating other cancers driven by MYC and could lead to efficient new drugs.
Researchers discovered that blocking PHLPP2 enzyme halts prostate cancer growth and metastasis without signs of toxicity in mice or human cells. This finding presents a promising approach for treating prostate cancer and potentially other types of cancers.
Abnormal chromosome number abnormalities are linked to increased risk of lethal disease in prostate cancer patients. Patients with five or more predicted aneuploidy alterations had a 5.3 times higher odds of lethal cancer during follow-up.
The Damon Runyon Physician-Scientist Training Award provides physicians with research skills and experience to become leaders in translational and clinical research. The award addresses financial burdens that deter physicians from pursuing a research career, offering up to $460,000 over four years.
Researchers found higher levels of aneuploidy lead to greater lethality risk among prostate cancer patients, suggesting a possible way to predict prognosis and inform treatment. The study also identified chromosomes 7 and 8 as commonly aneuploid in prostate tumors.
Researchers discovered that low levels of syntaphilin at the central core of prostate tumors correlate with increased risk of metastasis. The biomarker may identify patients who require more aggressive management and treatment.
A new study published in the Journal of Urology found that transperineal prostate biopsies (TPBx) under local anesthetic are the safest method for testing and diagnosing prostate cancer, with fewer complications and improved patient tolerability.
Researchers have identified a gene mutation in prostate cancer that is linked to poor survival and increased relapse rates. The study found that men with this mutation are more than three times as likely to die and nearly seven times as likely to relapse on standard treatments.
Research reveals men treated for benign prostatic hyperplasia (BPH) with 5-α-reductase inhibitors experienced a two-year delay in prostate cancer diagnosis and were twice as likely to have advanced disease. PSA suppression from these medications led to delays in diagnosis, potentially resulting in worsened clinical outcomes.
A new imaging technique using subharmonic contrast-enhanced ultrasound may help detect prostate cancer in patients where MRI is negative. The study, to be presented at the ARRS Annual Meeting, found that the technique detected PCa in 9 of 31 patients with a prior negative MRI or biopsy.
A study of 429 men with metastatic castration-resistant prostate cancer found correlations between specific genetic alterations and clinical outcomes. The loss of the RB1 tumor suppressor gene was significantly correlated with poor survival in patients treated with androgen receptor signaling inhibitors.
Researchers at Karolinska Institutet have identified blood-based biomarkers that can determine which patients with advanced prostate cancer will benefit from continued hormonal therapy. The study suggests that patients with a normal TP53 gene and fewer AR resistance markers may benefit more from treatment.
A single high-dose treatment has shown promise in treating men with low-risk prostate cancer, reducing the need for multiple visits to the hospital. After two years, 94% of patients showed no sign of cancer returning, while those with medium-risk cancer saw a 95% success rate.
Research by UBC's Men's Health Research Program reveals that many men struggle with understanding prostate cancer diagnosis and treatment options. The study highlights the importance of health literacy in making informed decisions and managing personal health.
A recent UBC study found that a 'reduced workload' program is the best option for men recovering from a radical prostatectomy, reducing the risk of burnout and promoting full recovery. The researchers recommend that patients have an open conversation with their employer before surgery to come up with a plan for a gradual return to work.
Global prostate cancer incidence and mortality rates are decreasing or stabilizing, with the US experiencing a significant decline. The study highlights improvements in detection practices and treatment, but notes that PSA screening may contribute to diagnosis at later stages and higher mortality rates.
Researchers at the University of Bradford discovered a protein, EN2, released by cancer cells that alters normal cell behavior, promoting tumour growth and evading the immune system. The study found that both cancer and normal cells take up the protein, leading to changes in shape or fusion, allowing cancer cells to reactivate and spread.